Biosimilars are the grand experiment. If the biosimilar experiment succeeds, competition will lead to lower prices and increase access for patients. However, if biosimilar competition does not advance the result may be price controls. This could decrease the incentive to innovate and lead to fewer new drugs being developed. Biologics are among the highest priced […]
generics
Coalition Letter To Senate: Increase Drug Competition
Today, forty-five organizations sent a letter to the US Senate calling for an end to the anticompetitive abuses that block competitive market entry by generic drug makers, which work to keep drug prices higher. A copy of the letter is available here.
Coalition Letter Opposes Maryland Prescription Law
Today, a coalition of organizations sent a letter to Maryland Governor Hogan objecting to a bill that gives the State’s Attorney General additional authority over competitive generic drug pricing — drugs that are typically 80% lower than their name brand counterparts. The letter is signed by American Consumer Institute, Consumer Action for a Strong Economy, FreedomWorks, Frontiers of Freedom, Independent Women’s […]
Hill’s Congress Blog: Caution–Drug Competition Not Allowed
About thirty years ago, generic (unbranded) drugs were first approved by the Federal Drug Administration (FDA) for use by patients. These drugs provided competitive alternatives to more expensive name branded pharmaceuticals, and this competition saved consumers $1.68 trillion (not billion) over the last decade, according to the FDA’s Deputy Commissioner. Lower prices from these alternatives […]
ACI in the Huffington Post: FDA Delays Will Cost Money and Lives
This article, written by ACI president Steve Pociask, discusses the benefits of biosimilar dugs. These drugs are generic-like versions of lifesaving brand named biopharmaceutical drugs, called biologics. Europe has had biosimilar competition since 2006, but the U.S. has yet to approve a single biosimilar drug for U.S. patients. The article calls on the FDA to accelerate its rulemaking and write […]
ACI in Real Clear Policy: Progress on Biosimilars – Not Fast Enough
Drugs that compete with brand-name drugs are usually called “generics.” Off-brand products that compete with an especially complex category of drugs called “biologics,” however, are called “biosimilars.” Whereas generics are chemically identical to brand-name drugs, the FDA defines a biosimilar as having a new active ingredient while being highly similar to the reference product and […]
ACI Expert to Speak on Biosimilars and Protecting R&D Dollars
Professor Joseph Fuhr Jr., ACI Senior Fellow and professor of Economics at Widener University, will be speaking on the challenges, lessons and opportunities in the marketing of biosimilars in the U.S. at the BioNJ Breakfast Salon in Bridgewater, NJ on June 2, 2011.